Oxyrane develops enzyme replacement therapies (ERTs) for lysosomal storage diseases with a lead program targeting Pompe disease. The company uses a proprietary Yarrowia lipolytica yeast platform to produce therapeutic proteins with homogeneous human sugar structures, yielding 3–15× more mannose 6‑phosphate and delivering over a 20‑fold improvement in cellular uptake versus current processes. Oxyrane plans to use new capital to advance its lead ERT from preclinical stages through the end of Phase I/II and to continue preclinical development of additional ERT candidates. Founded in 2006 and led by CEO Michael Campbell, Oxyrane is based in Manchester, England and maintains research facilities in Ghent, Belgium. The company emphasizes improved targeting and uptake of lysosomal enzymes without altering the natural proteins. No revenue or user metrics were disclosed in the article.

Total raised

$27M

Funding rounds

1

Latest round

Series D

Latest activity

Nov 2011